Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q4 FY2025 Earnings Presentation
35 slides from Piramal Pharma's earnings presentation, May 15, 2025
Slide 1: Exchange filing cover letter
14th May, 2025 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Press Release and Investor Presentation – Audited Financial Res
Slide 2: Piramal Pharma Limited Announces Results for Q4 and FY2025
PRESS RELEASE Piramal Pharma Limited Announces Results for Q4 and FY2025 Mumbai, India | May 14, 2025: Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceuticals and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and
Slide 3: Key Business Highlights for Q4 and FY2025
Key Business Highlights for Q4 and FY2025 Contract Development and Manufacturing Organization (CDMO): - Increasing contribution from Innovation1 related work - Up from 50% in FY24 to 54% in FY25, driven by commercial manufacturing of on-patent molecules - Robust growth in on-patent commercial manufa
Slide 4: Consolidated Profit and Loss Statement
Consolidated Profit and Loss Statement (in ₹ Crores or as stated) Quarterly Full Year Particulars Q4FY25 Q4FY24 YoY Change FY25 FY24 YoY Change Revenue from Operations 2,754 2,552 8% 9,151 8,171 12% Other Income 42 26 59% 135 175 (23%) Total Income 2,796 2,579 8% 9,286 8,347 11% Material Cost 955 1,
Slide 5: Q4FY25/FY25 Earnings Conference Call
Q4FY25/FY25 Earnings Conference Call Piramal Pharma Limited will be hosting a conference call for investors / analysts on 15th May 2025 from 9:30 AM to 10:15 AM (IST) to discuss its Q4 and FY25 Results. The dial-in details for the call are as under: Event Location & Time Telephone Number +91 22 6280
Slide 6: Q4 & FY25 Results
Q4 & FY25 Results Piramal May 2025 Pharma Limited
Slide 7: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner,
Slide 8: FY2024 and FY2025 – Two Good Years of Significant Recovery
FY2024 and FY2025 – Two Good Years of Significant Recovery Revenue from Operations EBITDA & EBITDA Margin Net Profit After Tax Net Debt to EBITDA (In ₹ Crore) (EBITDA: In ₹ Crore) EBITDA Margin (In ₹ Crore) 12% 17% 150 00% 200 000% 600 % 180 000% 100 00% 500 % 160 000% 91 500 0% 140 000% 400 % 120 0
Slide 9: Key Highlights of the Quarter – Q4FY2025
Key Highlights of the Quarter – Q4FY2025 Revenue from Operations EBITDA & EBITDA Margin Net Profit After Tax1 (In ₹ Crore) (EBITDA: In ₹ Crore) EBITDA Margin (In ₹ Crore) 8% 22% 22% 52% 2,754 603 2,552 154 556 101 Q4FY24 Q4FY25 Q4FY24 Q4FY25 Q4FY24 Q4FY25 Q4FY25 – Q4 has historically been the bigges
Slide 10: Key Highlights of the Year Gone By – FY2025
Key Highlights of the Year Gone By – FY2025 FY25 – A steady year with 12% revenue & 15% EBITDA growth, and over 5x YoY increase in net profit after tax CDMO CHG ICH • Share of Innovation Related Work • Maintained #1 Rank in the US • Power Brands - Delivered a healthy 54% in FY25 Vs. 50% in FY24 Sevo
Slide 11: Global Footprint with a Diversified Revenue Base
Global Footprint with a Diversified Revenue Base 17 100+ ~500 6,000+ Manufacturing and Countries with CDMO customers CHG customers development sites1 commercial presence (Hospitals) Total FY25 Revenue by Geography Total FY25 Revenue by Segments Others North 12% America India Consumer Healthcare 36%
Slide 12: Business Wise Performance
Business Wise Performance
Slide 13: CDMO Business
CDMO Business Performance Highlights Revenue Growth (In ₹ Crore) FY2025 – 15% revenue growth accompanied by EBITDA margin expansion • More than 50% share of Innovation1 related work - 54% in FY25 vs 50% in FY24, driven by commercial manufacturing of on-patent molecules 8% 15% • On-patent commercia
Slide 14: Deep Pipeline of Development Projects across Multiple Phases
Deep Pipeline of Development Projects across Multiple Phases Revenue by Services Building Development Pipeline Across Clinical Phases Others1, 17% Pre-clinical, 1% Pre-Clinical Phase I Phase II Phase III 2% 54% Innovation 25% FY25 2.8x 145 related Development work 27% Revenue by Phase I, Phase III,
Slide 15: Diversified Blue Chip Customer Base
Diversified Blue Chip Customer Base Customer Mix Revenue Concentration #1 Generics 22% 30% 59% of revenue from Big Over 500 customers Pharma and Emerging #2 across segments 5% Biopharma #3 Big Pharma Others 4% 43% 52% #4 3% Others 11% Top 5-10 Emerging Biopharma 14% 16% Long Standing Relationships w
Slide 16: Growth in Revenue and Contribution from Differentiated Offerings
Growth in Revenue and Contribution from Differentiated Offerings Revenue (US$ mn) from Contribution of Differentiated Offerings Differentiated Offerings to CDMO revenue Potent sterile Peptide injectables Differentiated High Potent On-patent API Differentiated Offerings API development and Offerings
Slide 17: Globally Diversified Manufacturing Footprint
Globally Diversified Manufacturing Footprint UK / Europe 2 Facilities 5. Grangemouth 6. Morpeth Total 15 Facilities 5 1 2 6 3 4 India 9 Facilities 7. Ahmedabad1 8. Rabale 9. Turbhe 10. Mahad 7 8 14 11. Digwal 12. Hyderabad2 North America 4 Facilities 9 11 13. Ennore 14. Pithampur 12 1. Aurora 2. Sel
Slide 18: Maintaining our Best-in-Class Quality Track Record
Maintaining our Best-in-Class Quality Track Record 375+ Regulatory Inspections with no OAI ~130 Audits Annually by Customers US FDA Inspections Other Regulatory Inspections 44 36 36 36 197 35 167 163 172 165 29 29 157 148 26 27 140 141 25 116 115 42 99 17 32 32 14 35 34 13 21 26 71 10 20 24 29 60 10
Slide 19: Complex Hospital Generics Business
Complex Hospital Generics Business Performance Highlights Revenue Growth (In ₹ Crore) Inhalation Anesthesia • Major GPO contract renewal and order wins supporting IA sales in the US 6% 8% • #1 Rank in Sevoflurane in the US with 44%1 market share • Setting up of Sevoflurane manufacturing lines in I
Slide 20: CHG Revenues by Product Segment and Geography
CHG Revenues by Product Segment and Geography Revenue by Product Segment Revenue by Geography % FY25 CHG Revenue Inhalation Anesthesia Intrathecal Therapy Others 20% (67%) (15%) India 5% FY25 CHG US 56% Revenue Japan 4% Injectable Anesthesia and Other Speciality Products Pain Management (10%) (8%) E
Slide 21: Unlocking Sevoflurane Opportunity Across RoW Markets
Page 16 Unlocking Sevoflurane Opportunity Across RoW Markets Over US$400mn Sevoflurane Market in RoW US$1bn Global IA Market US$850+ mn Global Sevoflurane Market Desflurane 12% China 31% US PPL is market leader with 44% market share Isoflurane 21% 2% US$400mn Market Opportunity • PPL current market
Slide 22: Neoatricon® - Approval for Multiple Markets in EU and UK
Page 17 Neoatricon® - Approval for Multiple Markets in EU and UK A Cardiovascular Drug for Neonates, Infants and Children Currently, there are no approved Dopamine Hydrochloride formulations specifically indicated for use in neonates, infants, or children, with off-label use remaining a common pract
Slide 23: India Consumer Healthcare Business
India Consumer Healthcare Business Performance Highlights Revenue Growth (In ₹ Crore) New Product launches - 21 new products and 31 new SKUs launched in FY25. Products launched in last 24 months contributed 8% to ICH sales 15% 11% Power Brands grew 22%/20% YoY during Q4FY25/FY25, 274 1,0 contrib
Slide 24: Focus on Power Brands with Brand Promotion and Marketing
Page 19 Focus on Power Brands with Brand Promotion and Marketing Investments in Brand Promotion and Marketing (In ₹ Crore) % of ICH 15% 15% 13% 11% sales Little’s Tetmosol CIR 131 131 125 Wipes, Toys, Diapers, Medicated Soap, Adult Diapers, 115 Feeding Range Cream & Powder Bed Bath Wipes FY22 FY23 F
Slide 25: Multi-channel Distribution Network and Tech-enabled Sales
Page 20 Multi-channel Distribution Network and Tech-enabled Sales Presence Across Traditional And Alternate Trade Channels Wide coverage across Strengthening presence Expanding presence on Direct-to-Customer (D2C) general trade and chemist in modern trade E-Commerce Presence in ~180K chemists Presen
Slide 26: Abbvie Therapeutics India Private Limited
Page 21 Abbvie Therapeutics India Private Limited Joint Venture Arrangement Ownership Ownership 49% 51% In FY2025, the JV reported# revenue of ₹493 Cr. with PAT margin of 28% Continue to be one of the Strong presence in 400+ Key Brands market leaders glaucoma, dry Refresh, Ozurdex, in the Indian emp
Slide 27: Financials
Financials
Slide 28: Consolidated Financials Highlights
Consolidated Financials Highlights (in ₹ Cr. or as stated) Particulars Q4FY25 Q4FY24 YoY Change FY25 FY24 YoY Change Revenue from Operations1 2,754 2,552 8% 9,151 8,171 12% CDMO 1,788 1,649 8% 5,447 4,750 15% CHG 705 667 6% 2,633 2,449 8% ICH 274 238 15% 1,093 985 11% EBITDA 603 556 8% 1,580 1,372 1
Slide 29: Consolidated Financials Highlights
Consolidated Financials Highlights (In ₹ Crore) Key Balance Sheet Items As on 31-Mar-25 As on 31-Mar-24 Total Equity 8,125 7,911 Net Debt 4,199 3,932 Total 12,324 11,843 Net Fixed Assets 9,110 9,106 Tangible Assets 4,534 4,250 Intangible Assets including goodwill 3,599 3,740 CWIP (including IAUD*) 9
Slide 30: Reiterating our FY2030 Aspirations
Reiterating our FY2030 Aspirations
Slide 31: Financial Aspirations for FY2030
Financial Aspirations for FY2030 3x 2x 1x Over 3x Growth in More than Double the Reduce Leverage EBITDA Revenues on the Balance Sheet ~25% US$2+ Bn ~1x EBITDA Margins Revenue NetdebttoEBITDA Exponential Growth Enhance ROCE in PAT Early Teens PAT Margins High Teens ROCE Note:- The aspirations mention
Slide 32: US$2+ Bn Company with 25% EBITDA Margin by FY2030
US$2+ Bn Company with 25% EDITDA Margin by FY2030 Strategic Goals for FY2030 US$1.2 Bn revenues with ~25% US$600 Mn revenues with 25%+ US$200 Mn revenues with double-digit EBITDA margin EBITDA margin EBITDA margin CDMO CHG ICH Emerge as a fast-growing, innovation- Become a leading critical carecompa
Slide 33: Key Investment Highlights
Key Investment Highlights US$2+ Bn Global Pharma, Health & Wellness Company by FY2030 1 Strong promoter group with over 35 years of demonstrated ability to build scalable and differentiated businesses 2 Presence in large multi-billion dollar size attractive industry segments with promising tailwinds
Slide 34: Dial-in Details for Q4 and FY25 Earnings Conference Call
Dial-in Details for Q4 and FY25 Earnings Conference Call Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 09:30 AM IST 1 800 120 1221 (Toll free number) USA – 12:00 AM Toll free number Conference call (Eastern Time – New York) 18667462133 on 15th Ma
Slide 35: For Investor Queries
For Investor Queries: Gagan Borana Madhusudan Dalmia Investor Relations and Enterprise Risk Management Investor Relations Email: gagan.borana@piramal.com Email: madhusudan.dalmia@piramal.com Our Websites:- Piramal Pharma Limited CDMO www.piramalpharma.com www.piramalpharmasolutions.com Complex Hospi